台灣腸道醫學會

01/11/2025

🌿 年底最值得期待的腸道盛會來啦！
【台灣腸道醫學會 2025 第四次學術討論會】
📅 12/13（六）12:50–17:30
📅 12/14（日）08:30–11:50
📍高雄翰品酒店 6F 春耕廳

這次議程陣容堅強、主題多元，
從臨床案例、內視鏡決策到微菌治療與精準醫療，兩天滿滿乾貨，讓你一次掌握 IBD 以及腸道疾病最新趨勢🔥

💡 重點議程搶先看：

🩺 Case Files from the Frontline
蔡韙仲 醫師、許思齊 醫師
臨床現場的抉擇與驚喜，
從真實案例看醫師的臨床思維

🧫 Bugs as Drugs? The Future of Microbiota-Based Therapies - From Next-Gen Probiotics to FMT
邱政洵 副院長
從 FMT 到次世代益菌，揭開腸道微菌治療新篇章

💉 Infliximab Never Gets Old: Why the Pioneer Biologic Still Matters in the Era of Abundance
蔡騌圳 主任
經典生物製劑依然屹立不搖，無法取代！談療效與臨床角色

🎯 Targeting the Gut, Sparing the Rest: Gut-Selective Biologics in IBD
莊喬雄 主任
如何兼顧療效與安全？IBD 腸道專一性場生物製劑的治療策略全面解析

🧠 When Polyps Tell a Story: Endoscopic Diagnosis, Therapy, and Surveillance in Peutz-Jeghers Syndrome
章振旺 主任
Peutz–Jeghers 症候群的診斷與追蹤實務

⚖️ Shaping Health, Not Just Bodies
周莒光 主任
從臨床醫師視角打造健康體重中心的全新藍圖

💪 The Hidden Shield: Vaccination in IBD Patients
周仁偉 主任
發炎性腸道疾病病友如何聰明接種？疫苗策略全攻略

⚡ Dual-Acting IL-23 in IBD Treatment Is Coming: A New Era to Anticipate
鍾承軒 主任
雙重作用的抗IL23生物製劑開啟 IBD 治療新時代

🔬 Precision Power: Selective JAK Inhibitors Reshaping IBD Therapy
李柏賢 主任
小分子時代的精準治療，談個人化 IBD 照護的未來

📷 Capsule Endoscopy in IBD: Expanding the Horizon of Small Bowel Assessment
顏旭亭 主任
膠囊鏡帶你探索小腸世界的新視界

📊 From Data to Impact: TASID Study Progress
林士驊 醫師
首度公開台灣多中心 UST 實證研究成果！

兩天議程橫跨臨床實務、創新療法與研究應用，
讓你一次更新腸道醫學的全貌！邀請所有醫師、護理師、營養師、藥師一起來高雄學習交流最新、最熱門的腸道疾病照護知識🔥

—————

🌿 The Most Anticipated Gastroenterology Event of the Year Is Here!
TASID 4th Academic Meeting of 2025
📅 December 13 (Sat) 12:50–17:30
📅 December 14 (Sun) 08:30–11:50
📍 Han-Hsien International Hotel, Kaohsiung – 6F, Chungheng Hall

This two-day forum brings together leading experts to explore everything from real-world clinical challenges and endoscopic decision-making to microbiota therapy and precision IBD management 🔥

💡 Program Highlights:

🩺 Case Files from the Frontline
Clinical decision-making in action — revealing the art and science behind complex IBD cases.

🧫 Bugs as Drugs? The Future of Microbiota-Based Therapies – From Next-Gen Probiotics to FMT
— redefining microbiome-based therapy.

💉 Infliximab Never Gets Old: Why the Pioneer Biologic Still Matters
The classic biologic remains irreplaceable — its enduring efficacy and role in modern IBD care.

🎯 Targeting the Gut, Sparing the Rest: Gut-Selective Biologics in IBD
Balancing efficacy and safety through gut-selective therapeutic strategies.

🧠 When Polyps Tell a Story: Endoscopic Diagnosis, Therapy, and Surveillance in Peutz–Jeghers Syndrome
Practical insights from detection to cancer prevention.

⚖️ Shaping Health, Not Just Bodies
Building a holistic weight management model from a gastroenterologist’s perspective.

💪 The Hidden Shield: Vaccination in IBD Patients
Smart vaccination strategies for IBD patients under immunomodulatory therapy.

⚡ Dual-Acting IL-23 in IBD Treatment: A New Era to Anticipate
Dual blockade therapy ushers in the next chapter of IBD management.

🔬 Precision Power: Selective JAK Inhibitors Reshaping IBD Therapy
Personalized care in the small molecule era — precision-driven treatment for IBD.

📷 Capsule Endoscopy in IBD: Expanding the Horizon of Small Bowel Assessment
Exploring the small intestine through the lens of capsule endoscopy.

📊 From Data to Impact: TASID Study Progress
First multicenter real-world insights on Ustekinumab across Taiwan.

Two full sessions bridging clinical experience, innovation, and research —
Join us in Kaohsiung to exchange the latest and most practical knowledge in intestinal health and IBD care! 🌱

#台灣腸道醫學會 #腸道醫學 #發炎性腸道疾病 #臨床實證 #內視鏡 #醫護進修 #學術研討會

01/11/2025

🌿 腸保健康・南區病友會圓滿成功！

從腸道出發，從交流開始💬
今天在成功大學醫學院舉辦的「腸保健康 病友會」，
現場氣氛溫馨熱烈，超過90位病友與家屬齊聚一堂，一起關心腸道、分享經驗、交換照護心法。

感謝莊喬雄主任的用心籌辦，
章振旺秘書長特地到場開場致詞，
南區多位 IBD 專家熱情分享，
凡華與鈺淳夥伴也全程協助。

在講者與病友的互動中，
從「腸道保健」到「低發炎飲食」，
每一段討論都充滿實用與關懷。

誠摯感謝所有醫師、志工與合作廠商的支持，
讓這場病友會不只是學習，更是一份力量的連結💪
期待未來，
我們能繼續陪伴病友，
一起邁向更好的腸健康🌱

—————

🌿 Gut Health Patient Meeting – Southern Region Successfully Concluded!

Starting from the gut, and from genuine conversations 💬

Today’s “Gut Health Patient Meeting”, held at National Cheng Kung University (NCKU) College of Medicine, was filled with warmth and enthusiasm.
Over ninety patients and family members gathered to learn about intestinal health, share experiences, and exchange care insights.

The event featured thoughtful organization, an inspiring opening address, and enthusiastic sharing from multiple IBD experts in southern Taiwan.
Supportive partners were also present throughout, ensuring everything ran smoothly.

Through engaging discussions between speakers and participants —
from “gut care” to “anti-inflammatory diets” —
every session was full of practical wisdom and heartfelt empathy.

We sincerely thank all physicians, volunteers, and partner organizations for their contribution.
This gathering was not just about learning, but about building a network of strength and hope 💪

Looking ahead,
we will continue to accompany our patients —
together toward a healthier, happier gut 🌱

#腸保健康 #台灣腸道醫學會
#發炎性腸道疾病 #克隆氏症 #潰瘍性結腸炎
#病友會 #腸道健康 #患者支持 #健康生活

29/10/2025

👩‍⚕️👨‍⚕️ IBD 治療進入新篇章！

真實世界證據（RWE）如何改變臨床決策？
台日專家首次同台，
帶你看見從臨床到創新治療的跨國經驗！

🌿【TASID GutTalk｜IBD RWE Exchange Forum】
跨國視野 × 真實世界證據 × 新興治療分享

💡 想了解台灣與日本在 IBD 實證照護的最新進展嗎？

這場論壇邀請

🇹🇼 長庚醫院 李柏賢 主任
🇯🇵 北里大學 Dr. Taku Kobayashi

從臨床真實世界資料（RWE）出發，
帶來兩地在生物製劑與 IL-23 抑制劑的寶貴經驗分享。

📅 時間｜ 2025年11月7日（週五）19:30 – 21:00

🩺 主持人｜
台灣腸道醫學會 郭昭宏 理事長
三軍總醫院 黃天祐 主任

🎯 講題亮點
19:30 – 20:00｜台灣 IBD 真實世界資料：臨床洞見與在地實踐（李柏賢 主任）

20:00 – 20:30｜日本 IBD 實證經驗與 IL-23 新治療觀察（Dr. Taku Kobayashi）

20:30 – 21:00｜雙方深度對談與現場 Q&A

🧠 從「數據」到「臨床決策」，一次掌握 IBD 治療的最新趨勢。誠摯邀請全國醫師、護理師與醫事人員踴躍報名，一起站在國際前沿，從真實世界找到實證答案！

📍 歡迎對IBD診治有興趣的醫護人員以及個管師踴躍報名參加❤️報名連結請見留言處😊

—————

👩‍⚕️👨‍⚕️ A New Chapter in IBD Treatment Begins!

How is real-world evidence (RWE) transforming clinical decision-making?
For the first time, experts from Taiwan and Japan share the stage — offering cross-national insights from clinical experience to innovative therapies.

🌿 【TASID GutTalk｜IBD RWE Exchange Forum】
Global Perspectives × Real-World Evidence × Emerging Therapies

💡 Curious about the latest real-world advances in IBD care across Taiwan and Japan?
Join this special forum featuring:

🇹🇼 Dr. Puo-Hsien Le, Chang Gung Memorial Hospital
🇯🇵 Dr. Taku Kobayashi, Kitasato University

Together, they will present real-world findings and clinical experiences on biologic and IL-23 inhibitor therapies in IBD management.

📅 Date & Time｜ Friday, November 7, 2025 ｜ 19:30–21:00 (Taipei Time)

🩺 Moderators｜
🔅Dr. Chao-Hung Kuo, President, Taiwan Association for the Study of Intestinal Diseases (TASID)
🔅 Dr. Tien-Yu Huang, Tri-Service General Hospital

🎯 Program Highlights
19:30 – 20:00｜ Real-World Data in Taiwan IBD Care: Clinical Insights and Local Practice — Dr. Puo-Hsien Le
20:00 – 20:30｜ Real-World Experience and IL-23 Therapy in Japan — Dr. Taku Kobayashi
20:30 – 21:00｜ Expert Dialogue and Live Q&A

🧠 From data to clinical decisions, gain a comprehensive view of the evolving landscape of IBD treatment.
We sincerely invite physicians, nurses, and allied health professionals to join us and explore how real-world evidence is shaping the future of precision IBD care.

📍 Registration link in the comments — all healthcare professionals interested in IBD care are warmly welcome! ❤️

#真實世界證據 #臨床教育 #台灣腸道醫學會 #李柏賢 #黃天祐 #郭昭宏

27/10/2025

很開心今晚有 110 位對IBD照護充滿熱忱的醫護夥伴
一起線上參與這場台韓IBD臨床經驗交流會 🧠💬

從治療策略到整合照護，從臨床實證到病人關懷，
每一次跨國交流，都是讓 IBD 照護更進步的一步。

感謝所有參與者與幕後團隊的用心💪
期待我們一起讓照護更全面、讓病人更安心。

#整合照護 #台韓交流 #實證醫學 #腸道醫學會 #章振旺 #蘇銘堯

25/10/2025

🌟台灣首次真實世界研究證實——Risankizumab在亞洲克隆氏症患者中展現顯著療效！
📍克隆氏症（Crohn’s disease） 是一種慢性腸道發炎疾病，長期造成腹痛、腹瀉、體重下降與生活品質受損。
對於中重度患者，傳統藥物常無法有效控制症狀，需要盡早給予進階藥物(包括生物製劑或小分子藥物)治療。

💊 最新由 台灣七大醫學中心 共同完成的「STAR研究」發現：
使用 Risankizumab（RZB，抗IL-23p19單株抗體） 治療中重度克隆氏症患者，
在短短12週內誘導治療即展現令人振奮的成果👇

✨ 治療成效
91.8% 病人症狀明顯改善
42.9% 達到臨床緩解（症狀接近消失）
超過半數病人回報生活品質顯著提升

即使曾用過其他生物製劑者，RZB 仍具明顯療效

🩺 安全性良好
研究期間無嚴重副作用，僅少數出現輕微頭痛或肝功能變化
成果發表於國際SCI期刊 (Therapeutic Advances in Gastroenterology)。

💬 研究意義
這是亞洲第一項以真實世界數據（Real-World Data）評估Risankizumab的研究。
結果顯示此藥在台灣病人中同樣安全、有效，為克隆氏症治療開啟新篇章！

📢 給病友的提醒：
若您或親友飽受中重度腸道發炎困擾，可與胃腸肝膽科醫師討論新一代生物製劑治療的可能性。

🌟 Real-world study in Taiwan confirms: Risankizumab offers strong results for Crohn’s disease patients in Asia!

📍Crohn’s disease is a chronic inflammatory condition that can cause severe abdominal pain, diarrhea, and fatigue.
Managing moderate-to-severe cases has long been a major challenge.

💊 The STAR study, conducted across seven leading hospitals in Taiwan, is the first real-world evidence in Asia showing that Risankizumab (RZB) — an anti–IL-23p19 monoclonal antibody — is both effective and safe for treating Crohn’s disease

TAG Published.

✨ Key Results (after 12 weeks):
91.8% of patients showed clinical improvement
42.9% achieved remission (symptom-free)
Over half reported significant quality-of-life improvements

Strong results were seen even in patients who had failed previous biologic treatments.

🩺 Safety:
No severe adverse events occurred; only mild headache or transient liver enzyme elevation were noted.

💬 Why It Matters:
This landmark study provides the first real-world evidence in Asia supporting Risankizumab as a reliable, effective induction therapy for Crohn’s disease.
It gives new hope for patients who struggle to control inflammation with existing treatments.

📢 If you’re living with Crohn’s disease, talk to your gastroenterologist about new biologic therapies like Risankizumab that could help you regain control of your health.

#克隆氏症 #真實世界數據 #台灣研究

22/10/2025

🌿【TASID GutTalk｜台韓聯合 IBD 專題】

📅 10月27日（週一）19:00–20:10（台灣時間）
由 台灣腸道醫學會（TASID） 與 艾伯維 AbbVie 共同舉辦

FutureIBD Webinar：Taking an evidence-based approach for holistic IBD care from Taiwan and Korea

這場跨國線上會議將以臨床案例為核心，帶您看見：

✅ 達標治療（Treat-to-target）策略與黏膜癒合
✅ Data / Evidence 驅動的臨床決策
✅ 多專科團隊（MDT）整合照護
✅ 非侵入性監測於 IBD 照護中的角色

⸻

🎤 講者陣容
🇹🇼 Dr. Chen-Wang Chang（章振旺 醫師）
　 台北馬偕紀念醫院 胃腸肝膽科

🇰🇷 Dr. Sang Hyoung Park
　 韓國 Asan Medical Center

主持人：
Dr. Ming-Yao Su（蘇銘堯 醫師）
新北市立土城醫院

⸻

💬 誠摯邀請醫護夥伴們
在忙碌的一天結束後，吃完晚餐、端起茶杯 ☕
輕鬆打開連結，與來自台韓的專家們一起學習、交流、啟發新思維！

🔗 報名方式：
👉 點擊留言區連結，或掃描圖片右側 QR code 報名參加。

⸻

🌿 [TASID GutTalk｜Korea–Taiwan Joint IBD Webinar]

📅 October 27 (Mon), 19:00–20:10 (Taiwan Time)
Jointly organized by the Taiwan Association for the Study of Intestinal Diseases (TASID) and AbbVie,

FutureIBD Webinar: Taking an evidence-based approach for holistic IBD care from Taiwan and Korea

This cross-country online session will center around real clinical cases, highlighting:

✅ Treat-to-target strategy and mucosal healing
✅ Data- and evidence-driven clinical decisions
✅ Multidisciplinary team (MDT) collaboration
✅ The role of non-invasive monitoring in IBD management

⸻

🎤 Speakers
🇹🇼 Dr. Chen-Wang Chang
　Division of Gastroenterology and Hepatology, Mackay Memorial Hospital, Taipei

🇰🇷 Dr. Sang Hyoung Park
　Asan Medical Center, Korea

Moderator
Dr. Ming-Yao Su
New Taipei Municipal TuCheng Hospital

⸻

💬 We warmly invite all IBD care professionals—
After a busy day, take a seat, enjoy your evening tea ☕,
and join us online for an inspiring session of learning and sharing with experts from Taiwan and Korea!

🔗 Registration:
👉 Click the link in the comments or scan the QR code on the poster to register.

#腸道健康 #克隆氏症 #潰瘍性結腸炎 #多專科照護

18/10/2025

🩺 胃鏡愈普及，胃部「隱藏腫瘤」發現愈多！
胃部黏膜下或上皮下腫瘤，你了解多少？

隨著胃鏡檢查越來越普遍，醫師發現更多胃部黏膜下（Submucosal tumors SMTs）或上皮下腫瘤（Subepithelial tumors, SETs）。
📊 整體盛行率約 2%，但70 歲以上長者可能高達 10%。
其中約有 2–8% 的病灶在 2–5 年內會變大，需要密切追蹤。
⚠️ 特別要注意的是，胃腸道基質瘤（Gastrointestinal Stromal Tumor, GIST)，這類腫瘤多從胃壁肌肉層長出，屬於惡性腫瘤，不管多大皆需及早切除。

根據台灣癌症登錄資料：
胃的惡性腫瘤第一名仍是常見的胃腺癌（Adenocarcinoma）
第二名則是GIST！
👉 GIST 在 2017 年占胃惡性腫瘤的 5.55%，到了 2022 年竟高達 22.65%，以 每年約 1.4 倍速度增加！

過去治療多靠外科手術切除部分胃部，
但隨著內視鏡技術進步，現在可利用經口胃鏡進行
「胃壁全層切除」加上「內視鏡縫合關閉」，
能免開刀、無體表傷口，保留大部分正常胃部、恢復更快、生活品質更好✨

🌍 Hidden Gastric Tumors Are on the Rise — What You Should Know

With the growing use of gastroscopy, doctors are discovering more submucosal or subepithelial tumors (SMTs or SETs) in the stomach.
📊 Overall prevalence: ~2%, but can reach up to 10% in people over 70. About 2–8% of these lesions may grow within 2–5 years, requiring close monitoring.
⚠️ Among them, Gastrointestinal Stromal Tumors (GISTs) are of particular concern —
they originate from the muscular layer of the stomach wall and are malignant, meaning surgical removal is necessary.

📈 According to Taiwan’s Cancer Registry:
The most common gastric malignancy is adenocarcinoma
The second most common is GIST!
👉 GISTs made up 5.55% of gastric cancers in 2017, and surged to 22.65% by 2022, growing about 1.4× each year!

Traditionally, surgery involved partial removal of the stomach.
However, with advanced endoscopic techniques, doctors can now perform full-thickness resection of the gastric wall and endoscopic closure —
All through the mouth, without external incisions.
This minimally invasive approach allows faster recovery and better quality of life 🌟

05/10/2025

29/09/2025

🌟【TASID 在台灣消化醫學週的精彩回顧】🌟

9/27–9/28 的台灣消化醫學週，台灣腸道醫學會（TASID）帶來了一系列關於發炎性腸道疾病（IBD）的重磅分享！💡

🍴 9/27 中午 Symposium
👨‍⚕️ 鍾承軒 主任帶來 Upadacitinib 在 IBD 的療效，並分享臨床案例，讓治療策略更有畫面感。

🌍 9/27 下午 Symposium — Holistic Care in IBD
從不同角度，探討 IBD 的「全方位照護」：
✨ Saruta 教授：如何掌握 UC 的裡急後重的症狀
✨ 章振旺 主任：IBD 與高齡化
✨ 郭家榮 主任：肥胖與 IBD 治療
✨ 林敬斌 主任：IBD病人的懷孕安全 & very early-onset IBD的治療

📖 9/28 早上 Special Lecture
Saruta 教授帶來專題：
IBD in Asia: Bridging the present and shaping the future
👉 從亞洲視角出發，展望 IBD 的未來！

💬 這兩天的學術交流，不只分享了最新療法，更關注病人的全人照護。TASID 期待與大家一起，為 IBD 病人打造更完整、更溫暖的醫療支持！💪❤️

#台灣腸道醫學會 #發炎性腸道疾病 #克隆氏症 #潰瘍性結腸炎 #台灣消化醫學週

29/09/2025

💩 點『屎』成金 ：什麼是腸道微菌叢移植術（FMT）？
您知道腸道裡有超過一百兆的「好菌」和「壞菌」共同生活嗎？當這些菌群失去平衡，就可能導致疾病。FMT（fecal microbiota transplantation，腸道微菌叢移植術）是一種新興的治療方式，主要是將健康捐贈者的腸道菌群（通常經過處理成懸液或膠囊形式）移植到病人的腸道中，以重建或調整受試者的腸道微生態平衡。
🎉 臨床應用
目前唯一公認且效果最明確的適應症是復發性困難梭狀桿菌感染（Recurrent or refractory Clostridioides difficile infection, CDI）：FMT 的治癒率可以達到 80–90% 以上，相比於傳統抗生素治療好上許多。
🎉 潛在研究中的適應症
o 發炎性腸道疾病（IBD）：例如 ulcerative colitis（潰瘍性結腸炎）、Crohn’s disease，但療效還在探索中。如最近刊登於消化期刊，針對FMT在潰瘍性結腸炎治療的系統性回顧《Gut Microbiota Features in Relation to F***l Microbiota Transplantation Outcome in Ulcerative Colitis: A Systematic Review and Meta-Analysis》 (CGH, 2025) 中提到，FMT 在潰瘍性結腸炎（UC）可誘導部分患者緩解，但療效差異大，成功與否與「腸道微生物多樣性α-diversit）」高度相關。有療效的可能特徵，包含高 α-多樣性（在捐贈者與接受者的治療前治療後皆適用）; 富含 產丁酸的菌種（butyrate-producing species）。療效不佳的臨床特徵包含：低多樣性、菌群單一（例如 Bacteroides 過度優勢）等。
o 代謝疾病：肥胖、糖尿病、脂肪肝等，透過改變腸道菌群影響代謝途徑。
o 免疫相關疾病：包括自體免疫疾病、移植後的免疫調控（如GVHD）。
o 腦腸軸相關疾病：如憂鬱症、自閉症、帕金森氏症，研究中但尚未確立。
🎉移植方式
• 下消化道：大腸鏡、灌腸。
• 上消化道：鼻胃管、鼻空腸管。
• 口服：冷凍乾燥製成的口服膠囊。
🎉台灣的現況與法規
依據台灣衛生福利部的規範，目前 FMT 僅限用於多次復發的困難梭狀桿菌感染，而且必須在合格的醫療院所，由專業醫師操作。捐贈者需要經過嚴格的血液與糞便檢驗，以排除傳染病與其他風險，確保治療安全。
🎉其他研究方向
國際及國內有許多研究正在探索 FMT 在發炎性腸道疾病（IBD）、代謝疾病（如肥胖、糖尿病、脂肪肝）、甚至神經與免疫相關疾病的可能效果。不過，這些仍屬於臨床試驗階段，尚未成為正式適應症。

⚠️給民眾的提醒
FMT 並不是「偏方」或「萬靈藥」，而是一種有嚴格規範的醫療程序，還是有一定的可能風險，例如：感染傳播風險（因此需要嚴格的捐贈者篩檢），移植物中可能攜帶未知病原或不良菌群。長期安全性仍在觀察中。若您或家人有反覆的困難梭狀桿菌感染，建議與專業醫師討論 FMT 是否合適。請勿自行嘗試或購買來路不明的產品，以免帶來感染風險。
引用來源：Clinical Gastroenterology and Hepatology 2025;23:1719–1736

💩What is F***l Microbiota Transplantation (FMT)?
Did you know that your gut contains more than 100 trillion bacteria, both “good” and “bad”? When this delicate balance is disrupted, disease can occur. F***l Microbiota Transplantation (FMT) is a medical procedure in which stool from a carefully screened healthy donor is processed and transplanted into a patient’s intestines. The goal is to restore a healthier gut microbiome.

Proven Clinical Evidence
Scientific studies have shown that FMT is highly effective for treating recurrent Clostridioides difficile infection (CDI). CDI is a serious bacterial infection that often comes back even after antibiotics. While traditional treatment may fail, FMT has been proven to cure 80–90% of patients, making it far more successful than medication alone.

Regulations in Taiwan
In Taiwan, according to the Ministry of Health and Welfare, FMT is approved only for patients with multiple recurrences of CDI. The procedure must be performed in qualified hospitals by trained gastroenterologists. Donors go through strict blood and stool testing to rule out infectious diseases and other risks, ensuring that the treatment is as safe as possible.

Other Research Areas
Around the world, researchers are exploring the use of FMT in conditions such as inflammatory bowel disease (IBD), metabolic diseases (obesity, diabetes, fatty liver), immune disorders, and even neurological conditions. However, these are still under investigation and not officially approved indications. More high-quality clinical trials are needed before they can become standard treatments.
Important Reminders
FMT is not a folk remedy or a miracle cure. It is a regulated medical procedure with strict donor screening and safety protocols. If you or your family members suffer from recurrent CDI, you may discuss with your gastroenterologist whether FMT is suitable. Please do not attempt self-treatment or purchase unverified FMT products online, as this may lead to serious infections or complications.

28/09/2025

📸TASID 影像瑰寶 ImaGems EP4：黑漆漆的大腸黏膜
這是腸道醫學會（TASID）影像教育系列 — 影像瑰寶（ImaGems） 的第四集。藉由這些珍貴影像，我們希望呈現臨床上具有教育意義的典型表現，並促進醫師間的專業交流與醫學教育。
🔥每一張影像，都是臨床診斷的瑰寶
👉今天要帶大家看看一張相當特殊的大腸鏡影像！一位 55 歲女性因為持續的腹痛接受檢查，結果在 X 光與電腦斷層上發現「像樹枝般彎曲的血管鈣化」；大腸鏡則看到大腸黏膜呈現異常的黑紫色 病理切片進一步證實，這是一個極罕見的疾病。
❓ 你覺得這樣的的內視鏡影像，最可能提示哪一種病理診斷呢？

✍作者：呂貞燕醫師、鍾承軒醫師
答案將在留言處揭曉 (文獻來源: Radiology 2021 Dec;301(3):735-740.
doi: 10.1148/radiol.2021201802.)
僅供 TASID 會員教育之用
————————————
📸TASID ImaGems EP4: Blackish mucosa of colon
This is the third episode of the TASID Imaging Education Series — ImaGems. Through these valuable images, we aim to highlight classic and educational endoscopic findings, fostering professional exchange and medical education among clinicians.
🔥Every image is a clinical gem
👉Today, we are going to take a look at a very unusual colonoscopy image! A 55-year-old woman underwent evaluation for persistent abdominal pain, and imaging studies (X-ray and CT) revealed branch-like, tortuous vascular calcifications. Colonoscopy further showed abnormally dark-purple colonic mucosa. Pathology confirmed that this was an extremely rare disease. .

❓What pathological diagnosis do you think this rare endoscopic finding suggests?

✍ Authors: Chen-Yen Lu, Chen-Shuan Chung
The answer will be revealed in the comments (Reference: Radiology 2021 Dec;301(3):735-740. doi: 10.1148/radiol.2021201802.)
For TASID members’ education only

28/09/2025

📸 TASID 影像瑰寶 ImaGems EP3：長毛的大腸息肉

這是腸道醫學會（TASID）影像教育系列 — 影像瑰寶（ImaGems） 的第三集。藉由這些珍貴影像，我們希望呈現臨床上具有教育意義的典型表現，並促進醫師間的專業交流與醫學教育。

✨ 每一張影像，都是臨床診斷的瑰寶 ✨

🥢 今天要帶大家看看一張相當特殊的大腸鏡影像！一位 32 歲女性因腹痛與腹瀉接受檢查，在乙狀結腸發現一個長有毛髮的有梗瘜肉狀病灶🌱

👉 你覺得這樣的的內視鏡影像，最可能提示哪一種病理診斷呢？

✍️ 作者：李柏賢醫師、鄒永寬醫師、吳仁欽醫師

📌 答案將在留言處揭曉 📝

🎓 僅供 TASID 會員教育之用

————————————

📸 TASID ImaGems EP3: A Hairy Colonic Polyp

This is the third episode of the TASID Imaging Education Series — ImaGems. Through these valuable images, we aim to highlight classic and educational endoscopic findings, fostering professional exchange and medical education among clinicians.

✨ Every image is a clinical gem ✨

🥢 Today, let’s take a look at a very unusual colonoscopic image!
A 32-year-old woman presented with abdominal pain and diarrhea, and during colonoscopy, a polypoid lesion covered with hair was found in the sigmoid colon 🌱.

👉 What pathological diagnosis do you think this rare endoscopic finding suggests?

✍️ Authors: Puo-Hsien Le, Yung-Kuan Tsou, Ren-Chin Wu

📌 The answer will be revealed in the comments 📝

🎓 For TASID members’ education only

#腸道醫學會 #李柏賢 #吳仁欽